Trial Profile
Clinical Trials Insight: 700053467
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2010
Price :
$35
*
At a glance
- Drugs Bremelanotide (Primary) ; Type 5 cyclic nucleotide phosphodiesterase inhibitors
- Indications Erectile dysfunction
- Focus Therapeutic Use
- 17 Aug 2010 In the fourth quarter of 2010, Palatin Technologies expects to meet with the FDA to discuss initiation of this trial.